The transformation of the pharmaceutical industry has brought development opportunities, and pharmaceutical machinery companies are accelerating the expansion of growth space

【Pharmaceutical Network Market Analysis】In recent years, the pharmaceutical industry has been affected
by heavy policies such as the acceleration of drug approval, the promotion of consistency evaluation of generic drugs, the "4+7" volume procurement, the release of the new version of the basic drug catalog, and the adjustment of the medical insurance catalog 。 Under the changes in the pharmaceutical industry, pharmaceutical machine companies are accelerating the expansion of growth space (Image source: Pharma.
com) It is understood that in the current process of tightening drug supervision, pharmaceutical companies, especially pharmaceutical manufacturers that have won bids and entered the medical insurance catalog, are paying more and more attention to drug quality and the economy and stability
of production.
Based on this trend, assisting pharmaceutical companies to improve process flow and reduce costs has become one of
the main development trends in the pharmaceutical equipment industry.
Taking Canaan Technology as an example, it has been accelerating innovation and upgrading around automation, continuity, greening and
intelligence in recent years.
At present, Canaan Technology's solid preparation equipment is equipped with a self-developed set of adaptive, self-driven, self-adjusting SMART system, which can be automatically adjusted according to the current materials to achieve cost-effective production parameters, and even how many products can be produced per kilowatt hour can be accurately calculated, which is convenient for pharmaceutical companies to compare and statistically
carry out costs.
In addition, in the recycling of steam, water and other resources, the company also has corresponding functional equipment to match
.
It is worth noting that in order to open up the upstream and downstream to expand the growth space, Canaan Technology said that the future business focus will shift from production to service, and products will extend
from pharmaceutical stand-alone machines to complete lines and overall solutions.
At the same time, it will continue to be deeply involved in the entire life cycle of drugs, from front-end research and development to the final drug production, the company can provide a complete set of solutions
.
At present, with the rapid development of the biomedical industry, the bioengineering sector is also providing more opportunities
for pharmaceutical enterprises.
In order to seize the opportunity, further meet the demand for biopharmaceuticals and expand new performance growth points, many pharmaceutical companies have also increased their layout in the field of
bioengineering.
Among them, Chutian Technology has introduced a number of experts in the front-end field of bioengineering in the past two years to carry out product research and development, promotion and sales quickly
.
In the first half of this year, this segment accounted for a relatively large number of products such as liquid preparation systems, bioreactors, chromatography, ultrafiltration systems, SUTs and microspheres
.
Bioengineering is more
relevant to downstream customers' processes than aseptic dispensing and post-test package products.
It is reported that Chutian plans to transform from equipment-based overall solutions to technology-based overall solution providers, of which bioengineering will be the focus of
the company's future development.
In addition, Dongfulong also publicly stated last year that it would firmly focus on the development strategy of "systematization, internationalization and digitalization", in the field of sterile injections, bioengineering and other pharmaceutical equipment, closely focus on the production process and development direction of drugs, develop innovative products with forward-looking and independent intellectual property rights, improve R&D efficiency, increase innovation, and provide global pharmaceutical customers with competitive and brand influence of overall system solutions
.
On July 13 this year, Dongfulong also issued the "Announcement on the Company's Issuance of Shares to Specific Targets and Approved by the Listing Review Center of the Shenzhen Stock Exchange"
.
It is planned to raise funds for the biopharmaceutical equipment industry trial production center project, the Jiangsu biomedical equipment industrialization base project, and the life science industrialization base project of Zhejiang Dongfulong Biotechnology Co.
, Ltd.
to supplement the working capital
.
The industry believes that due to the benefits brought by the policy side and the demand side, China's pharmaceutical equipment industry is showing a good development trend
.
Related enterprises are also following the development trend of the industry, accelerating diversified development, and opening up more new markets
.
It is expected that in the future, as the policy side and the demand side continue to provide development momentum, pharmaceutical machinery companies will usher in more rich development opportunities
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.